The Novel Atypical Dopamine Uptake Inhibitor (S)-CE-123 Partially Reverses the Effort-Related Effects of the Dopamine Depleting Agent Tetrabenazine and Increases Progressive Ratio Responding

  • Front Pharmacol. 2019 Jun 28:10:682. doi: 10.3389/fphar.2019.00682.
Renee A Rotolo  1 ,  Vladimir Dragacevic  2 ,  Predrag Kalaba  2 ,  Ernst Urban  2 ,  Martin Zehl  3 ,  Alexander Roller  4 ,  Judith Wackerlig  2 ,  Thierry Langer  2 ,  Marco Pistis  5 ,  Maria Antonietta De Luca  5 ,  Francesca Caria  5 ,  Rebecca Schwartz  1 ,  Rose E Presby  1 ,  Jen-Hau Yang  1 ,  Shanna Samels  1 ,  Merce Correa  1  6 ,  Gert Lubec  7 ,  John D Salamone  1
Affiliations
  • 1. Department of Psychological Sciences, University of Connecticut, Storrs, CT, United States.
  • 2. Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Vienna, Austria.
  • 3. Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.
  • 4. X-ray Structure Analysis Centre, Faculty of Chemistry, University of Vienna, Vienna, Austria.
  • 5. Department of Biomedical Sciences, University of Cagliari, National Institute of Neuroscience (INN), Cagliari, Italy.
  • 6. Àrea de Psicobiologia, Universitat Jaume I, Castelló, Spain.
  • 7. Department of Neuroproteomics, Paracelsus Medical University, Salzburg, Austria.
Abstract

Animal studies of effort-based choice behavior are being used to model effort-related motivational dysfunctions in humans. With these procedures, Animals are offered a choice between high-effort instrumental actions leading to highly valued reinforcers vs. low effort/low reward options. Several previous studies have shown that dopamine (DA) uptake inhibitors, including GBR12909, lisdexamfetamine, methylphenidate, and PRX-14040, can reverse the effort-related effects of the vesicular monoamine transport blocker tetrabenazine, which inhibits DA storage. Because many drugs that block DA transport act as major stimulants that also release DA, and produce a number of undesirable side effects, there is a need to develop and characterize novel atypical DA transport inhibitors. (S)-CE-123 ((S)-5-((benzhydrylsulfinyl) methyl)thiazole) is a recently developed analog of modafinil with the biochemical characteristics of an atypical DA transport blocker. The present paper describes the enantioselective synthesis and initial chemical characterization of (S)-CE-123, as well as behavioral experiments involving effort-based choice and microdialysis studies of extracellular DA. Rats were assessed using the fixed ratio 5/chow feeding choice test. Tetrabenazine (1.0 mg/kg) shifted choice behavior, decreasing lever pressing and increasing chow intake. (S)-CE-123 was coadministered at doses ranging from 6.0 to 24.0 mg/kg, and the highest dose partially but significantly reversed the effects of tetrabenazine, although this dose had no effect on fixed ratio responding when administered alone. Additional experiments showed that (S)-CE-123 significantly increased lever pressing on a progressive ratio/chow feeding choice task and that the effective dose (24.0 mg/kg) increased extracellular DA in nucleus accumbens core. In summary, (S)-CE-123 has the behavioral and neurochemical profile of a compound that can block DA transport, reverse the effort-related effects of tetrabenazine, and increase selection of high-effort progressive ratio responding. This suggests that (S)-CE-123 or a similar compound could be useful as a treatment for effort-related motivational dysfunction in humans.

Keywords
anergia; depression; dopamine; fatigue; modafinil; motivation; synthesis; transport.
Products